Concepedia

Patrick M. McDaneld

PM

Statistics

Publications

6

Citations

373

H-Index

6

Active since

2009

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

The University of Texas Health Science Center at Houston

Cubist Pharmaceuticals (United States)

Massachusetts College of Pharmacy and Health Sciences

University of Nebraska Medical Center

Patrick M. McDaneld is an author at The University of Texas MD Anderson Cancer Center specializing in antimicrobial resistance, antibiotics, and medicine.

ORCID

Top concepts

Publications per year

2009–2022

6

Publications

6

<i>In Vitro</i> Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy

Kady Phe, Yuman Lee, Patrick M. McDaneld et al. · Antimicrobial Agents and Chemotherapy · 2014 · 178 citations · Full text

, , +15

Assessing Appropriateness of Antimicrobial Therapy: In the Eye of the Interpreter

Daryl D. DePestel, Edward H. Eiland, Katherine Lusardi et al. · Clinical Infectious Diseases · 2014 · 53 citations · Full text

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors

Peter L. Anderson, Christina L. Aquilante, Edward M. Gardner et al. · Journal of Antimicrobial Chemotherapy · 2009 · 48 citations · Full text

Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant <i>Enterobacterales</i> Bloodstream Infections

William C. Shropshire, Anna Konovalova, Patrick M. McDaneld et al. · mSystems · 2022 · 35 citations · Full text

Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing <i>Escherichia coli</i> in Patients with Hematologic Malignancy

Grace Benanti, Anne Rain Brown, Terri Lynn Shigle et al. · Antimicrobial Agents and Chemotherapy · 2018 · 33 citations · Full text

1–5 of 6